Zevra Therapeutics, Inc. (ZVRA) P/E Ratio History
Historical price-to-earnings valuation from 2022 to 2026
Loading P/E history...
ZVRA Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Zevra Therapeutics, Inc. (ZVRA) trades at a price-to-earnings ratio of 8.1x, with a stock price of $11.00 and trailing twelve-month earnings per share of $2.06.
The current P/E is 83% below its 5-year average of 48.9x. Over the past five years, ZVRA's P/E has ranged from a low of 4.3x to a high of 169.9x, placing the current valuation at the 50th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, ZVRA trades at a 64% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, ZVRA trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ZVRA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ZVRA P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 9.9 | -Best | +68% | |
| $5B | 8.3Lowest | -Best | +264%Best | |
| $9B | 43.4 | -Best | +128% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ZVRA Historical P/E Data (2022–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $9.32 | $2.15 | 4.3x | -91% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $8.96 | $1.49 | 6.0x | -88% |
| FY2025 Q3 | $9.51 | $0.62 | 15.3x | -69% | |
| FY2022 Q1 | $5.03 | $0.03 | 169.9x | +248% |
Average P/E for displayed period: 48.9x
See ZVRA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ZVRA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ZVRA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonZVRA — Frequently Asked Questions
Quick answers to the most common questions about buying ZVRA stock.
Is ZVRA stock overvalued or undervalued?
ZVRA trades at 8.1x P/E, below its 5-year average of 48.9x. At the 50th percentile of historical range, the stock is priced at a discount to its own history.
How does ZVRA's valuation compare to peers?
Zevra Therapeutics, Inc. P/E of 8.1x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is ZVRA's PEG ratio?
ZVRA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2022-2026.